Home › Drugs A to Z › B › Be › Bevacizumab Pregnancy Warnings
Print Save or Share

Bevacizumab Pregnancy and Breastfeeding Warnings

Bevacizumab is also known as: Avastin

Overview

Bevacizumab Solution may cause harm to the fetus. Do not become pregnant while you are using it. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Bevacizumab Solution while you are pregnant. If you are able to become pregnant, talk with your doctor or pharmacist about the use of effective birth control while taking Bevacizumab Solution and for at least 6 months following the last dose of Bevacizumab Solution. It is not known if Bevacizumab Solution is found in breast milk. Do not breast-feed while taking Bevacizumab Solution. Do not become pregnant or breast-feed immediately after you stop Bevacizumab Solution. Bevacizumab Solution can stay in your body for a long time after you stop using it. Talk with your doctor about when it may be safe to become pregnant or breast-feed.

Bevacizumab Pregnancy Warnings

Angiogenesis is critical to fetal development and the inhibition of angiogenesis following administration of bevacizumab is likely to result in adverse effects on pregnancy. Patients who discontinue bevacizumab should also be counseled concerning the prolonged exposure following discontinuation of therapy (half-life approximately 20 days) and the possible effects on fetal development.

Bevacizumab has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Bevacizumab should only be given during pregnancy when benefits outweigh risks.

Bevacizumab Breastfeeding Warnings

There are no data on the excretion of bevacizumab into human milk. Human IgG1 is secreted into human milk. The potential for absorption and harm to the infant after ingestion is unknown. Women should be advised to discontinue nursing during treatment with bevacizumab and for a prolonged period following therapy with bevacizumab, taking into account that the half-life averages approximately 20 days.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web5)